T
CRSP icon

Tidemark’s CRISPR Therapeutics CRSP Stock Holding History

Tidemark’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3K Hold
280
– – ﹤0.01% 453
2026
Q1 		$13.3K Hold
280
– – ﹤0.01% 430
2025
Q4 		$14.7K Sell
280
-137
-33% -$8.21K ﹤0.01% 391
2025
Q3 		$27K Hold
417
– – 0.01% 319
2025
Q2 		$20.3K Buy
417
+10
+2% +$387 0.01% 365
2025
Q1 		$13.8K Hold
407
– – 0.01% 391
2024
Q4 		$16K Hold
407
– – 0.01% 380
2024
Q3 		$19.1K Hold
407
– – 0.01% 343
2024
Q2 		$22K Buy
407
+137
+51% +$7.92K 0.01% 309
2024
Q1 		$18.4K Hold
270
– – 0.01% 345
2023
Q4 		$16.9K Buy
+270
New +$14.9K 0.01% 353

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tidemark's CRSP Position: Q2 2026 in Review

Tidemark held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 280 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #453.

Tidemark first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. The position peaked at $27K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Tidemark held 280 shares of CRISPR Therapeutics worth $15.3K as of Q2 2026.
  • Tidemark left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #453 holding.
  • Tidemark first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Tidemark's CRISPR Therapeutics position peaked at $27K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.